Results 61 to 70 of about 8,086 (190)

Height, Obesity, and the Risk of TMPRSS2:ERG-Defined Prostate Cancer. [PDF]

Cancer Epidemiol Biomarkers Prev, 2018
Abstract Background: The largest molecular subtype of primary prostate cancer is defined by the TMPRSS2:ERG gene fusion. Few studies, however, have investigated etiologic differences by TMPRSS2:ERG status. Because the fusion is hormone-regulated and a man's hormonal milieu varies by height and obesity status, we hypothesized that both ...
Graff RE, Ahearn TU, Pettersson A, Ebot EM, Gerke T, Penney KL, Wilson KM, Markt SC, Pernar CH, Gonzalez-Feliciano AG, Song M, Lis RT, Schmidt DR, Vander Heiden MG, Fiorentino M, Giovannucci EL, Loda M, Mucci LA.   +17 more
europepmc   +6 more sources

INTEGRATE-Neo: A pipeline for personalized gene fusion neoantigen discovery [PDF]

, 2016
Motivation While high-throughput sequencing (HTS) has been used successfully to discover tumor-specific mutant peptides (neoantigens) from somatic missense mutations, the field currently lacks a method for identifying which gene fusions
Maher, Christopher A, Mardis, Elaine R, Zhang, Jin   +2 more
core   +2 more sources

Transcriptional network analysis of PTEN‐protein‐deficient prostate tumors reveals robust stromal reprogramming and signs of senescent paracrine communication

Molecular Oncology, EarlyView.
Combining PTEN protein assessment and transcriptomic profiling of prostate tumors, we uncovered a network enriched in senescence and extracellular matrix (ECM) programs associated with PTEN loss and conserved in a mouse model. We show that PTEN‐deficient cells trigger paracrine remodeling of the surrounding stroma and this information could help ...
Ivana Rondon‐Lorefice, Jose I. Lopez, Aitziber Ugalde‐Olano, Maite Zufiaurre, Ianire Astobiza, Natalia Martin‐Martin, Laura Bozal‐Basterra, Saioa Garcia‐Longarte, Amaia Zabala‐Letona, Sofia Rey, Aida Santos‐Martin, Miguel Unda, Ana Loizaga‐Iriarte, Mariona Graupera, Paolo Nuciforo, Arkaitz Carracedo, Isabel Mendizabal   +16 more
wiley   +1 more source

TMPRSS2: ERG expression in prostate cancer—Imaging and clinicopathological correlations.

Journal of Clinical Oncology, 2020
284 Background: The TMPRSS2:ERG gene fusion (T:E) is found in up to 70% of prostate cancers (PCa) and results in androgen dependent overexpression of ERG, promoting tumor growth. The early identification of T:E may be helpful even in low-risk PCa. Although T:E can be non-invasively detected in urine, its correlation with new imaging tools (MRI and ...
V. Fasulo, M. Lazzeri, M. Corbetta, M. Paciotti, D. Maffei, R. Asselta, N. Frego, P. Diana, R. Contieri, A. Uleri, P. Casale, C. Chiereghin, A. Saita, G. Lughezzani, M. Zuradelli, R. Hurle, N. Buffi, G. Soldà, S. Duga, G. Guazzoni   +19 more
openaire   +2 more sources

The genomic evolution of human prostate cancer. [PDF]

, 2015
Prostate cancers are highly prevalent in the developed world, with inheritable risk contributing appreciably to tumour development. Genomic heterogeneity within individual prostate glands and between patients derives predominantly from structural ...
A Krohn, AA Al Olama, AH Reid, BS Carver, BS Taylor, CE Barbieri, CE Massie, CS Cooper, CS Grasso, D E Neal, G Gundem, H Hieronymus, J Lindberg, J Weischenfeldt, JB Hjelmborg, JC King, JL Williams, JP Theurillat, LB Alexandrov, M Kluth, MA Svensson, MF Berger, MK Hong, MM Shen, MS Lawrence, P Lichtenstein, R Eeles, S Steurer, SA Tomlins, SA Tomlins, SC Baca, T Mitchell, T Visakorpi, TI Zack, VM Raymond, Y Chen, Z Chen   +36 more
core   +2 more sources

Rapid Decentralized Prostate Cancer Risk Stratification by Portable Liquid Biopsy Analysis within a Clinical Biosensor Validation Framework

Advanced Science, EarlyView.
In this work, we showcased two significant scientific advances in (i) developing a portable biosensor technology for rapid decentralized prostate cancer urinary biomarker testing and reporting, with superior performance to current clinical testing practice; and (ii) proposing a clinical validation framework (for our biosensor development) which can be ...
Kevin M. Koo, Grant Phillips, Sriganesh Srihari, Áine Farrell, Binny Jaradi, Kira J. Fitzpatrick, John W. Yaxley, Hemamali Samaratunga, Paul N. Mainwaring, Ke‐lin Ru, Darren J. Korbie, Scott A. Tomlins, Matthew J. Roberts, Robert A. Gardiner, Matt Trau   +14 more
wiley   +1 more source

ERG signaling in prostate cancer is driven through PRMT5-dependent methylation of the Androgen Receptor

eLife, 2016
The TMPRSS2:ERG gene fusion is common in androgen receptor (AR) positive prostate cancers, yet its function remains poorly understood. From a screen for functionally relevant ERG interactors, we identify the arginine methyltransferase PRMT5. ERG recruits
Zineb Mounir, Joshua M Korn, Thomas Westerling, Fallon Lin, Christina A Kirby, Markus Schirle, Gregg McAllister, Greg Hoffman, Nadire Ramadan, Anke Hartung, Yan Feng, David Randal Kipp, Christopher Quinn, Michelle Fodor, Jason Baird, Marie Schoumacher, Ronald Meyer, James Deeds, Gilles Buchwalter, Travis Stams, Nicholas Keen, William R Sellers, Myles Brown, Raymond A Pagliarini   +23 more
doaj   +1 more source

Performance of PCA3 and TMPRSS2:ERG urinary biomarkers in prediction of biopsy outcome in the Canary Prostate Active Surveillance Study (PASS). [PDF]

, 2019
BackgroundFor men on active surveillance for prostate cancer, biomarkers may improve prediction of reclassification to higher grade or volume cancer.
Bianchi-Frias, Daniella, Brooks, James D, Brown, Marshall D, Carroll, Peter R, Cooperberg, Matthew R, Dash, Atreya, Fabrizio, Michael D, Faino, Anna V, Gleave, Martin E, Lin, Daniel W, Liss, Michael, Morgan, Todd M, Nelson, Peter S, Newcomb, Lisa F, Thompson, Ian M, Wagner, Andrew A, Zheng, Yingye   +16 more
core  

Role of dutasteride in pre‐clinical ETS fusion‐positive prostate cancer models [PDF]

, 2012
BACKGROUND Androgens play a crucial role in prostate cancer, hence the androgenic pathway has become an important target of therapeutic intervention.
Ateeq, Bushra, Cao, Qi, Lonigro, Robert J., Pienta, Kenneth J., Tomlins, Scott A., Varambally, Sooryanarayana, Vellaichamy, Adaikkalam, Wang, Rui   +7 more
core   +1 more source

Liquid biopsy in genitourinary oncology: Current clinical applications and future prospects across prostate, bladder, and renal cancers

UroPrecision, EarlyView.
Abstract Liquid biopsy has emerged as a transformative approach in oncology, providing minimally invasive access to tumor‐derived biomarkers with applications across diagnosis, prognosis, therapeutic guidance, and disease monitoring. This literature review synthesizes evidence from 125 studies evaluating circulating tumor DNA, circulating tumor cells ...
Kirolos Eskandar
wiley   +1 more source